Table 2

Adverse events

Symptom	Overall, n=13 pts. n (%)	Cohort DL1, n=3 pts.			Cohort DL2, n=4 pts.			Cohort DL3, n=6 pts.
Symptom	Overall, n=13 pts. n (%)	Grades 1&2	G 1	G 2	Grades 1&2	G 1	G 2	Grades 1&2	G 1	G 2
Fever	9 (69.2)	1 (33%)	1		2 (50%)	1	1	6 (100%)	5	1
Chills/rigor	9 (69.2)	2 (66%)	2		1 (25%)	1		6 (100%)	2	4
Hypotension	8 (61.5)				2 (50%)	2		6 (100%)	4	2
Fatigue	8 (61.5)	2 (66%)		2	3 (75%)	3		3 (50%)	3
Headache	6 (46.2)	1 (33%)	1		2 (50%)	2		3 (50%)	3
Nausea	5 (38.5)	2 (66%)	2					3 (50%)	3
Myalgia	5 (38.5)	1 (33%)		1	2 (50%)	2		2 (33%)	2
Vomiting	4 (30.8)				1 (25%)	1		3 (50%)	2	1
Dizziness	4 (30.8)				1 (25%)	1		3 (50%)	3
Tachycardia	3 (23.1)							3 (50%)	2	1
Malaise	2 (15.4)				1 (25%)	1		1 (16%)	1
Arthralgia	2 (15.4)	1 (33%)	1		1 (25%)	1
Anorexia	1 (7.7)				1 (25%)	1
Concentration impairment	1 (7.7)							1 (16%)	1
Delirium	1 (7.7)							1 (16%)	1
Itching	1 (7.7)							1 (16%)	1
Neuropathy	1 (7.7)							1 (16%)	1
Rash in arms	1 (7.7)							1 (16%)	1
Any symptoms	11 (84.6)

Adverse events considered at least potentially related to cytokine release syndrome summarized by subject and grade of severity.
DL, dose level; G, grade